Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Cardio-Renal Division Kicks Off August With Three Approvals

This article was originally published in The Pink Sheet Daily

Executive Summary

The Medicines Co.’s IV therapy Cleviprex plus Novartis’ drug-drug combos, Exforge and Diovan HCT, are approved.

You may also be interested in...



The Medicines Company’s Curacyte Acquisition Points To A Post-Angiomax Future

Deal expands TMC’s pipeline, with an eye on the antifibrinolytic market left empty by the Trasylol withdrawal.

The Medicines Company’s Curacyte Acquisition Points To A Post-Angiomax Future

Deal expands TMC’s pipeline, with an eye on the antifibrinolytic market left empty by the Trasylol withdrawal.

Wooing Partners, Pharmacopeia Shifts DARA To Kidney Disease

Cash-light firm’s move away from the crowded hypertension space could clinch a deal.

Related Content

Topics

UsernamePublicRestriction

Register

PS068292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel